Accelovance is an award winning, clinical development Contract Research Organization (CRO) focused on vaccine Phase I-III programs. Providing a full complement of global CRO services to pharmaceutical companies, biotechs; Accelovance supports client needs by leveraging operational knowledge and successful results including study execution, resourcing, pharmacovigilance/safety, site identification, and patient recruitment strategies. Accelovance has extensive experience managing Phase I, II and III pivotal vaccine studies, worked with novel technologies, recruited both healthy volunteers and target treatment populations; and successfully delivered non-traditional vaccine programs for biotech, government, and non-profit organizations.

Unique in comparison to most CROs, Accelovance provides complete clinical trial understanding and expertise by leveraging knowledge gained from our investigative site network subsidiary (Optimal Research), a US site management organization. Optimal is comprised of seven wholly-owned dedicated research centers, in addition to operating an extended oncology and pediatric site network. The importance and differentiation of Accelovance’s knowledge applied to sites globally and coupled with the therapeutic talent and experience of our team members, creates an intimate understanding of recruiting and managing patients within clinical trials. 

Our structure has created an intimate understanding of recruiting, enrolling, managing, and retaining patients in clinical trials. This valuable perspective, coupled with the talent and experience of our CRO team members, provides us with credible insight that we leverage to obtain operational efficiencies, enhance productivity, and ensure quality.

Accelovance is headquartered in Rockville, MD, and has offices in Stuart, FL; Chicago, IL; Peoria, IL; Boston, MA; Durham, NC; Philadelphia, PA; Beijing, China; Cambridge, UK; Wales, UK; ‘s-Hertogenbosch, the Netherlands; Moscow, Russia; and Jerusalem, Israel. For more information about Accelovance, visit our Web site at